879319-16-1

Basic information

• Product Name: 2-(2,5-dioxo-2',3'-dihydrospiro[imidazolidine-4,1'-indene]-1-yl)acetic acid
• CAS NO: 879319-16-1
• Molecular Weight: 260.249
• Mol File: 879319-16-1.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 2-(2,5-dioxo-2',3'-dihydrospiro[imidazolidine-4,1'-indene]-1-yl)acetic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(2,5-dioxo-2',3'-dihydrospiro[imidazolidine-4,1'-indene]-1-yl)acetic acid(879319-16-1)
• EPA Substance Registry System: 2-(2,5-dioxo-2',3'-dihydrospiro[imidazolidine-4,1'-indene]-1-yl)acetic acid(879319-16-1)

Safety Data

• Hazardous Substances Data: 879319-16-1(Hazardous Substances Data)

Usage

Molecular structure

A complex structure derived from spiro[imidazolidine-4,1'-indene].

Functional group

Contains a carboxylic acid functional group.

Potential applications

May have applications in pharmaceutical research and drug development.

Unique structure

The compound has a unique structure that may contribute to its potential biological activities.

Further research

Additional research is needed to fully understand the properties and potential uses of this compound.

Upstream product

• 1292292-81-9 (S)-butyl 1-(2,2,2-trifluoroacetamido)-2,3-dihydro-1H-indene-1-carboxylate 
• 166735-12-2 (S)-methyl 1-amino-2,3-dihydro-1H-indene-1-carboxylate 
• 6252-98-8 spiro[imidazolidine-4,1'-indan]-2,5-dione 
• 119511-77-2 ethyl 1-amino-2,3-dihydro-1H-indene-1-carboxylate 

Relevant articles and documents

Scaffold hybridization strategy towards potent hydroxamate-based inhibitors of: Flaviviridae viruses and Trypanosoma species

Infections with Flaviviridae viruses, such as hepatitis C virus (HCV) and dengue virus (DENV) pose global health threats. Infected individuals are at risk of developing chronic liver failure or haemorrhagic fever respectively, often with a fatal outcome if left untreated. Diseases caused by tropical parasites of the Trypanosoma species, T. brucei and T. cruzi, constitute significant socioeconomic burden in sub-Saharan Africa and continental Latin America, yet drug development is under-funded. Anti-HCV chemotherapy is associated with severe side effects and high cost, while dengue has no clinically approved therapy and antiparasitic drugs are outdated and difficult to administer. Moreover, drug resistance is an emerging concern. Consequently, the need for new revolutionary chemotherapies is urgent. By utilizing a molecular framework combination approach, we combined two distinct chemical entities with proven antiviral and trypanocidal activity into a novel hybrid scaffold attached by an acetohydroxamic acid group (CH2CONHOH), aiming at derivatives with dual activity. The novel spiro-carbocyclic substituted hydantoin analogues were rationally designed, synthesized and evaluated for their potency against three HCV genotypes (1b, 3a, 4a), DENV and two Trypanosoma species (T. brucei, T. cruzi). They exhibited significant EC50 values and remarkable selectivity indices. Several modifications were undertaken to further explore the structure activity relationships (SARs) and confirm the pivotal role of the acetohydroxamic acid metal binding group.